This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DMK Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de DMK Pharmaceuticals.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Sep 30

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Jul 29

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Jul 21

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Apr 13

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Jan 20

Adamis Pharmaceuticals: It's Now Or Never

Dec 02

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Sep 03

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Jun 13

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Jun 07

Adamis pharmaceuticals gets deficiency letter from NASDAQ

May 28

Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering

Jan 29

Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose

Nov 16

Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue

Nov 09

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como DMK Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OTCPK:DMKP.Q - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2023	4	-21	-9	-9	N/A
6/30/2023	5	-24	-13	-13	N/A
3/31/2023	5	-25	-21	-20	N/A
12/31/2022	5	-26	-27	-26	N/A
9/30/2022	1	-31	-32	-31	N/A
6/30/2022	1	-32	-34	-33	N/A
3/31/2022	2	-31	-41	-40	N/A
12/31/2021	2	-35	-39	-38	N/A
9/30/2021	4	-39	-37	-36	N/A
6/30/2021	4	-43	-33	-33	N/A
3/31/2021	0	-42	-22	-21	N/A
12/31/2020	3	-36	-21	-21	N/A
9/30/2020	8	-28	-19	-18	N/A
6/30/2020	13	-25	-18	-17	N/A
3/31/2020	22	-26	-17	-16	N/A
12/31/2019	22	-28	-23	-20	N/A
9/30/2019	21	-36	-32	-29	N/A
6/30/2019	19	-38	-37	-33	N/A
3/31/2019	17	-40	-38	-33	N/A
12/31/2018	15	-39	-36	-33	N/A
9/30/2018	14	-34	-29	-26	N/A
6/30/2018	13	-32	-23	-21	N/A
3/31/2018	13	-27	-22	-20	N/A
12/31/2017	13	-26	-17	-15	N/A
9/30/2017	13	-18	-15	-13	N/A
6/30/2017	11	-19	N/A	-17	N/A
3/31/2017	10	-20	N/A	-20	N/A
12/31/2016	6	-21	N/A	-21	N/A
9/30/2016	4	-24	N/A	-20	N/A
6/30/2016	2	-19	N/A	-16	N/A
3/31/2016	N/A	-17	N/A	-12	N/A
12/31/2015	N/A	-14	N/A	-10	N/A
9/30/2015	N/A	-14	N/A	-11	N/A
6/30/2015	N/A	-13	N/A	-10	N/A
3/31/2015	N/A	-12	N/A	-10	N/A
12/31/2014	N/A	-11	N/A	-9	N/A
9/30/2014	N/A	-12	N/A	-9	N/A
6/30/2014	N/A	-10	N/A	-8	N/A
3/31/2014	N/A	-8	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de DMKP.Q es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de DMKP.Q crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de DMKP.Q crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de DMKP.Q crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de DMKP.Q crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de DMKP.Q se prevé que sea elevada dentro de 3 años.

This company listing is no longer active

DMK Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals Corporation

First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation

Nasdaq to Delist Common Stock of DMK Pharmaceuticals

DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index

DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024

DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI

Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock Market

DMK Pharmaceuticals Corporation Announces CFO Changes

DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirements

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023

Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.

Adamis Pharmaceuticals Corporation Announces Chief Financial Officer Changes

Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023

Adamis Pharmaceuticals Corporation to Report Q3, 2022 Results on Nov 14, 2022

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Adamis Pharmaceutics Corporation Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation to Report Q2, 2022 Results on Aug 10, 2022

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of Covid-19

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Adamis Pharmaceuticals Corporation announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation Appoints Vickie Reed to Board of Directors

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Adamis Pharmaceuticals Corporation to Report Q1, 2022 Results on May 16, 2022

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Richard C. Williams Notifies Adamis Pharmaceuticals Corporation That Effective April 15, 2022, He Will Be Retiring

Adamis Pharmaceuticals Corporation’S Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

Adamis Pharmaceuticals Corporation Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Adamis Pharmaceuticals Corporation Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Adamis Pharmaceuticals Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 Mg Intramuscular Dose of Naloxone in Zimhi™

Adamis Pharmaceuticals: It's Now Or Never

Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

Adamis Pharmaceuticals Receives A Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

An unknown buyer completed the acquisition of U.S. Compounding, Inc. from Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) for $15 million.

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19

Adamis Provides Update on ZIMHI™

Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ

Adamis pharmaceuticals gets deficiency letter from NASDAQ

Adamis Pharmaceuticals Corporation announced delayed amended 10-Q filing

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

Adamis Pharmaceuticals Corporation announced delayed annual 10-K filing

Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the Covid-19 Challenged Hamster Model

Adamis Pharmaceuticals Corporation Clears to Proceed with Human Studies of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Strengthens Patent Portfolio for its Naloxone Product Candidate

Adamis Pharmaceuticals Corporation has completed a Follow-on Equity Offering in the amount of $44.999999 million.

Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering

Adamis Pharmaceuticals Corporation Announces the Availability of SYMJEPI Products in the Walgreens Prescription Savings Club

Adamis Pharmaceuticals Receives Complete Response Letter from the FDA Regarding ZIMHI

Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose

Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento